肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
登录/注册
VIP特权

文章目录

表达双特异性T细胞衔接器的过继转移T细胞在抗小鼠白血病中的活性增强

Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice

原文发布日期:2016-06-03

DOI: 10.1038/bcj.2016.38

类型: Original Article

开放获取: 是

英文摘要:

摘要翻译: 

原文链接:

文章:

表达双特异性T细胞衔接器的过继转移T细胞在抗小鼠白血病中的活性增强

Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice

原文发布日期:2016-06-03

DOI: 10.1038/bcj.2016.38

类型: Original Article

开放获取: 是

 

英文摘要:

Despite the impressive clinical efficacy of T cells engineered to express chimeric antigen receptors (CAR-Ts), the current applications of CAR-T cell therapy are limited by major treatment-related toxicity. Thus, safer yet effective alternative approaches must be developed. In this study, we compared CD19 bispecific T-cell engager (BiTE)-transferred T cells that had been transfected by RNA electroporation with CD19 CAR RNA-transferred T cells both in vitro and in an aggressive Nalm6 leukemia mouse model. BiTEs were secreted from the transferred T cells and enabled both the transferred and bystander T cells to specifically recognize CD19+ cell lines, with increased tumor killing ability, prolonged functional persistence, increased cytokine production and potent proliferation compared with the CAR-T cells. More interestingly, in comparison with CD3/CD28 bead-stimulated T cells, T cells that were expanded by a rapid T-cell expansion protocol (REP) showed enhanced anti-tumor activities for both CAR and BiTE RNA-electroporated T cells both in vitro and in a Nalm6 mouse model (P<0.01). Furthermore, the REP T cells with BiTE RNAs showed greater efficacy in the Nalm6 leukemia model compared with REP T cells with CAR RNA (P<0.05) and resulted in complete leukemia remission.

 

摘要翻译: 

尽管表达嵌合抗原受体(CAR-T)的T细胞在临床上展现出显著疗效,但当前CAR-T细胞疗法的应用仍受到治疗相关严重毒性的限制。因此,必须开发更安全且有效的替代方案。本研究通过RNA电转技术,对比了CD19双特异性T细胞衔接器(BiTE)修饰的T细胞与CD19 CAR RNA修饰的T细胞在体外及侵袭性Nalm6白血病小鼠模型中的表现。BiTE可从修饰的T细胞中分泌,使经修饰的T细胞及旁观T细胞均能特异性识别CD19+细胞系,与CAR-T细胞相比,其肿瘤杀伤能力增强、功能持续性延长、细胞因子分泌增加且增殖能力显著提升。更有趣的是,与CD3/CD28磁珠刺激的T细胞相比,采用快速T细胞扩增方案(REP)扩增的T细胞,在体外及Nalm6小鼠模型中均显示出更强的抗肿瘤活性(P<0.01)。此外,在Nalm6白血病模型中,携带BiTE RNA的REP T细胞比携带CAR RNA的REP T细胞具有更优的疗效(P<0.05),并实现了白血病的完全缓解。

 

原文链接:

Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice

相关文章

文章:肿瘤抗原优先来源于黑色素瘤和非小细胞肺癌中未突变的基因组序列
文章:年龄相关的烟酰胺腺嘌呤二核苷酸下降驱动CAR-T细胞衰竭
文章:MCSP+转移创始细胞在人类黑色素瘤转移定植早期激活免疫抑制
文章:脂质纳米颗粒递送合成抗原使实体瘤对car介导的细胞毒性敏感
文章:食管癌新辅助治疗中的进化和免疫微环境动力学
文章:CHD1缺失重编程srebp2驱动的胆固醇合成,在spop突变的前列腺肿瘤中促进雄激素响应性生长和去势抵抗
文章:对TIL细胞治疗无反应的转移性非小细胞肺癌患者的T细胞和新抗原保留受损的时间序列分析
文章:策展的癌细胞图谱提供了单细胞分辨率的肿瘤的全面表征
文章:以人群为基础的胶质瘤分子景观分析在青少年和年轻人揭示胶质瘤形成的见解
文章:肿瘤细胞上的PILRα与T细胞表面蛋白CD99相互作用抑制抗肿瘤免疫

……